In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...
This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...
RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Coughing, sneezing, wheezing? High fever and no sleep? Your child may have RSV.
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...